Absci Corp (ABSI)
4.21
-0.04
(-0.94%)
USD |
NASDAQ |
May 31, 16:00
4.19
-0.02
(-0.48%)
After-Hours: 20:00
Absci Revenue (Quarterly): 0.898M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.898M |
December 31, 2023 | 0.338M |
September 30, 2023 | 0.744M |
June 30, 2023 | 3.367M |
March 31, 2023 | 1.269M |
December 31, 2022 | 1.557M |
September 30, 2022 | 2.369M |
June 30, 2022 | 1.002M |
March 31, 2022 | 0.819M |
Date | Value |
---|---|
December 31, 2021 | 1.452M |
September 30, 2021 | 1.539M |
June 30, 2021 | 0.728M |
March 31, 2021 | 1.063M |
December 31, 2020 | 2.728M |
September 30, 2020 | 0.916M |
June 30, 2020 | 0.564M |
March 31, 2020 | 0.572M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.338M
Minimum
Dec 2023
3.367M
Maximum
Jun 2023
1.290M
Average
1.002M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
Eli Lilly and Co | 8.768B |
Creative Medical Technology Holdings Inc | -- |
CytomX Therapeutics Inc | 41.46M |
Bristol-Myers Squibb Co | 11.86B |
Recursion Pharmaceuticals Inc | 13.49M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -21.98M |
Total Expenses (Quarterly) | 24.40M |
EPS Diluted (Quarterly) | -0.22 |
Enterprise Value | 321.59M |
Profit Margin (Quarterly) | -2.45K% |
Earnings Yield | -27.55% |
Normalized Earnings Yield | -23.19 |